Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study by D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo

“…In 153 patients with severe liver fibrosis caused by hepatitis C virus (genotype 1), on background of triple AVT with telaprevir high level of immediate virologic response and low level of the preterm treatment discontinuation was marked.…”
Get full text

Results of the ORION open comparative randomized trial: evaluation of efficacy of the Russian drugs Altevir and Phosphogliv in combined treatment of chronic hepatitis C by V. T. Ivashkin, M. V. Mayevskaya, P. O. Bogomolov, I. G. Nikitin, A. O. Buyeverov, A. V. Lapshin

Subjects: “…chronic hepatitis c…”
Get full text

Gallbladder Wall Thickness as a Non-Invasive Tool for Prediction of Esophageal Varices in Patients with Hepatitis C Related Chronic Liver Disease by Munir Ahmed, Maliha Aziz, Shahzad Riyaz, Mohammad Salih, Rashed Nazir, Muslim Atiq

Subjects: Get full text

Seroprevalence of hepatitis B and C virus among a group of hemophilia patients in Kurdistan Region, Iraq by Salih A. Hama

Subjects: Get full text

Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy by K. R. Dudina, P. A. Belyy, I. V. Maev, N. Kh. Safiullina, E. A. Klimova, S. A. Shutko, O. O. Znoyko, N.  D. Yushchuk

Subjects: “…chronic hepatitis c…”
Get full text

The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i> by A. V. Lapshin, M. V. Mayevskaya, V. T. Ivashkin, P. O. Bogomolov, I. G. Nikitin, O. O. Znoyko

Subjects: “…chronic hepatitis c…”
Get full text

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study by V. T. Ivashkin, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, M. V. Mayevskaya, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda

Subjects: “…chronic hepatitis c…”
Get full text

Epidemiological Study of Hepatitis B, C and HIV Cases among the Foreigners Visiting Sulaimani City from 2013 Through 2016 by Mohammed Omer Mohammed, Asan Baram Hasan, Fenk Bakir Maarouf

Subjects: “…Hepatitis B, Hepatitis C, HIV, Prevalence, Foreigners,Sulaimani…”
Get full text

Global progress, challenges and strategies in eliminating public threat of viral hepatitis by Sihui Zhang, Fuqiang Cui

Subjects: Get full text

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study) by M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov

“…To estimate efficacy and safety of narlaprevir (NVR) with ritonavir (RTV), pegilated interferon (peg-IFN) and ribavirin (RBV) at treatmentnaïve and earlier treated noncirrhotic patients with chronic hepatitis C caused by the 1st virus genotype in double blind placebo-controlled 3rd phase study (PIONEER). …”
Get full text

Preliminary results of open comparative randomized study PHG-M3/P01-09 «ORION» on application of «Phosphogliv» in combined therapy of chronic hepatitis C by M. V. Mayevskaya

Subjects: “…chronic hepatitis c…”
Get full text

Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk by Núria Granel, Gemma Iserte, Concepció Bartres, Neus Llarch, Anna Pla, Víctor Sapena, Zoe Mariño, Sabela Lens, Ramón Vilana, Isabel Nuñez, Anna Darnell, Ernest Belmonte, Ángeles García-Criado, Alba Díaz, Marco Sanduzzi-Zamparelli, Carla Fuster, Sergio Muñoz-Martínez, Carmen Ayuso, Jordi Rimola, Alejandro Forner, Alexandre Soler, Ferran Torres, José Ríos, Jordi Bruix, Andrew M. Moon, Xavier Forns, María Reig

“…Abstract Background The eradication of the Hepatitis C Virus (HCV) reduce the risk of liver cancer (LC), but lifestyle changes after cure may counterbalance its benefit. …”
Get full text

Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C by V. T. Ivashkin, V. P. Chulanov, N. A. Mamonova, M. V. Maevskaya, M. S. Zharkova, I. N. Tikhonov, P. O. Bogomolov, E. V. Volchkova, A. S. Dmitriev, O. O. Znojko, E. A. Klimova, K. V. Kozlov, I. E. Kravchenko, E. Yu. Malinnikova, R. V. Maslennikov, M. I. Mikhailov, K. E. Novak, I. G. Nikitin, V. E. Syutkin, E. V. Esaulenko, A. A. Sheptulin, E. N. Shirokova, N. D. Yushchuk

Subjects: “…hepatitis c…”
Get full text

Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis by Liwei Zhuang, Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing, Huichun Xing

“…IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX), and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting.MethodsUsing the EMBASE, PubMed, and Cochrane Library databases, articles were screened from 1 January 2016 to 1 June 2024. …”
Get full text

Spontaneous splenic rupture associated with Q fever and portal hypertension: A case report by Cecil Mustafiz, Cecil Mustafiz, Deloshaan Subhaharan, Deloshaan Subhaharan, Daniel Chorley, Tariq Masood

Subjects: Get full text

Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy by V. E. Syutkin, V. P. Chulanov, I. V. Karandashova, V. A. Dolgin, A. O. Chugunov

Subjects: Get full text

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection by N. D. Yuschuk, S. L. Maximov, L. M. Ivanova, Ye. K. Klimova, O. O. Znoyko, A. V. Kravchenko

Subjects: “…chronic hepatitis c…”
Get full text

Role of alpha-fetoprotein in complex diagnostics of progressing course of chronic hepatitis B and C by I. A. Belavina, O. P. Dudanova

Subjects: Get full text

Risk of progression and the cause of mortality at chronic viral mixed-hepatitis by K. I. Yesmembetov, D. T. Abdurakhmanov, A. V. Odintsov, N. A. Mukhin

Subjects: Get full text

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment by M. V. Mayevskaya, I. N. Tikhonov, V. T. Ivashkin

Subjects: Get full text